The FDA announced steps to consolidate its fragmented adverse-event reporting systems into a single platform, the Adverse Event Monitoring System (AEMS). The agency said the move will centralize vaccine and product safety reports, improve transparency, and cut operating costs by replacing legacy databases. Officials stressed AEMS will not itself verify causation; reports remain unvetted signals that require follow-up epidemiology and review. Industry groups and safety experts reacted to the timeline and scope, noting that unified data access could speed signal detection but also magnify noise from passive reporting. The FDA framed AEMS as part of a broader transparency push to streamline post-market surveillance and support timely regulatory action. The change will affect manufacturers, hospitals and pharmacovigilance vendors that currently feed multiple legacy systems. Practical implications include new integration work for sponsors and labs to meet standardized submission formats and potential shifts in how companies triage safety signals. The agency said AEMS rollout will be phased and accompanied by guidance on interpretation, recordkeeping, and post-market study expectations.